Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Precigen price target lowered to $6 from $10 at H.C. Wainwright » 06:19
08/09/22
08/09
06:19
08/09/22
06:19
PGEN

Precigen

$2.07 /

-0.01 (-0.48%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Precigen to $6 from $10 and keeps a Buy rating on the shares post the Q2 results.

ShowHide Related Items >><<
PGEN Precigen
$2.07 /

-0.01 (-0.48%)

PGEN Precigen
$2.07 /

-0.01 (-0.48%)

07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
PGEN Precigen
$2.07 /

-0.01 (-0.48%)

Monday
Hot Stocks
Precigen expectsTrans Ova Genetics sale to close in Q3 » 16:27
08/08/22
08/08
16:27
08/08/22
16:27
PGEN

Precigen

$2.07 /

-0.01 (-0.48%)

"The transaction to…

"The transaction to sell Trans Ova Genetics, which is expected to close in Q3 2022, will provide Precigen with $170M in cash up-front and up to a $10M earn-out over the next two years. The proceeds from this sale will fortify our balance sheet and provide non-dilutive funds to pay our convertible notes, which we intend to do when due," said Harry Thomasian Jr., CFO of Precigen. "We believe that our cash on hand and cost reduction initiatives, taking into account our plan for our convertible notes, give us enough runway to advance our clinical priorities into Q4 2023."

ShowHide Related Items >><<
PGEN Precigen
$2.07 /

-0.01 (-0.48%)

PGEN Precigen
$2.07 /

-0.01 (-0.48%)

07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
PGEN Precigen
$2.07 /

-0.01 (-0.48%)

Earnings
Precigen reports Q2 EPS (13c), consensus (16c) » 16:25
08/08/22
08/08
16:25
08/08/22
16:25
PGEN

Precigen

$2.07 /

-0.01 (-0.48%)

Reports Q2 revenue…

Reports Q2 revenue $900,000, consensus $24.63M. "Precigen is laser focused on maximizing the value of our highest priority assets and prioritizing our capital allocation to enable us to reach critical inflection points in our clinical trials. We have been able to expedite our prioritized programs, rapidly progressing from Phase 1 dose escalations to 1b expansions and have already initiated Phase 2 studies for several programs," said Helen Sabzevari, President and CEO of Precigen. "We continue to demonstrate the potential of these assets and their associated therapeutic platforms, and are actively pursuing rapid regulatory strategies for licensure to bring these potential investigational therapies to patients as quickly as possible. We expect additional data this year and early next for our prioritized programs, and are particularly excited for the Phase 1 data presentation for the PRGN-2012 AdenoVerse study in Q4 2022."

ShowHide Related Items >><<
PGEN Precigen
$2.07 /

-0.01 (-0.48%)

PGEN Precigen
$2.07 /

-0.01 (-0.48%)

07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
PGEN Precigen
$2.07 /

-0.01 (-0.48%)

Over a month ago
Recommendations
Precigen subsidiary sale relieves convertible debt overhang, says Stifel » 13:52
07/05/22
07/05
13:52
07/05/22
13:52
PGEN

Precigen

$1.59 /

+0.19 (+13.62%)

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett said he is positive on Precigen's announcement of an agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, for $180M in total potential consideration as he sees the deal alleviating "a somewhat tenuous financing situation" given that the company has $200M in convertible debt maturing in July of 2023. The move to monetize this business came at a slightly higher price than he had anticipated, said Burnett, who remains positive on the potential for the company's manufacturing process to "bring allogeneic-like convenience with a lowered risk of product rejection." He maintains a Buy rating and $15 price target on Precigen shares.

ShowHide Related Items >><<
PGEN Precigen
$1.59 /

+0.19 (+13.62%)

PGEN Precigen
$1.59 /

+0.19 (+13.62%)

PGEN Precigen
$1.59 /

+0.19 (+13.62%)

Hot Stocks
Precigen enters agreement to divest non-healthcare subsidiary Trans Ova to URUS » 08:09
07/05/22
07/05
08:09
07/05/22
08:09
PGEN

Precigen

$1.41 /

+0.07 (+5.24%)

Precigen announced that…

Precigen announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics to URUS, a holding company with cooperative and private ownership, for $170M in upfront cash and up to $10M earn-out based on the performance of Trans Ova in 2022 and 2023. Consummation of the transaction, anticipated in Q3 2022, is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. "We believe this transaction will support Precigen's mission as a premier cell and gene therapy company laser focused on the rapid development of our top clinical assets to maximize shareholder value and potentially improve the way devastating diseases like cancer are treated," said Helen Sabzevari, PhD, President and CEO of Precigen. "I am proud of Precigen management and the Trans Ova team for successfully leading the financial turnaround of Trans Ova operations to maximize the value of this asset over the last two years. We expect to have the capacity to pay the convertible notes upon maturity and to focus on fast regulatory paths for our healthcare portfolio."

ShowHide Related Items >><<
PGEN Precigen
$1.41 /

+0.07 (+5.24%)

PGEN Precigen
$1.41 /

+0.07 (+5.24%)

PGEN Precigen
$1.41 /

+0.07 (+5.24%)

Over a quarter ago
Earnings
Precigen reports Q1 EPS (10c), consensus (13c) » 16:17
05/09/22
05/09
16:17
05/09/22
16:17
PGEN

Precigen

$1.16 /

-0.09 (-7.23%)

Reports Q1 revenue…

Reports Q1 revenue $32.0M, consensus $23.27M. "Precigen's portfolio has been prioritized based on the positive preliminary data we have seen for key programs and we are exploring potential rapid paths to licensure with the FDA for programs with compelling data in diseases that have a high unmet medical need. The FDA Fast Track designation recently received for PRGN-3006 UltraCAR-T will help facilitate development and expedite the review process and is an important milestone for patients with relapsed or refractory acute myeloid leukemia," said Helen Sabzevari, President and CEO of Precigen. "As a result of these advancements, we look forward to hosting a call to provide pipeline updates in the coming months."

ShowHide Related Items >><<
PGEN Precigen
$1.16 /

-0.09 (-7.23%)

PGEN Precigen
$1.16 /

-0.09 (-7.23%)

PGEN Precigen
$1.16 /

-0.09 (-7.23%)

Hot Stocks
Precigen says FDA grants Fast Track designation for PRGN-3006 UltraCAR-T » 08:07
04/04/22
04/04
08:07
04/04/22
08:07
PGEN

Precigen

$2.27 /

+0.15 (+7.08%)

Precigen announced that…

Precigen announced that the FDA has granted Fast Track designation for PRGN-3006 UltraCAR-T in patients with relapsed or refractory AML. PRGN-3006 was previously granted FDA Orphan Drug Designation.

ShowHide Related Items >><<
PGEN Precigen
$2.27 /

+0.15 (+7.08%)

PGEN Precigen
$2.27 /

+0.15 (+7.08%)

PGEN Precigen
$2.27 /

+0.15 (+7.08%)

Earnings
Precigen reports Q4 EPS (13c), consensus (14c) » 08:08
03/01/22
03/01
08:08
03/01/22
08:08
PGEN

Precigen

$2.23 /

+0.02 (+0.90%)

Reports Q4 revenue…

Reports Q4 revenue $24.22M, consensus $22.24M. The company anticipates that its cash, cash equivalents and short-term and long-term investments as of December 31, 2021 should enable the company to fund operations well into 2023, assuming the company's programs advance as currently contemplated; and the company's non-core businesses continued to generate increased revenues and profitability.

ShowHide Related Items >><<
PGEN Precigen
$2.23 /

+0.02 (+0.90%)

PGEN Precigen
$2.23 /

+0.02 (+0.90%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
PGEN Precigen
$2.23 /

+0.02 (+0.90%)

On The Fly
Short Report: GitLab short position re-accelerates to record high » 11:45
02/05/22
02/05
11:45
02/05/22
11:45
ATUS

Altice USA

$14.95 /

+0.01 (+0.07%)

, GTLB

GitLab

$72.47 /

+11.02 (+17.93%)

, FSR

Fisker

$11.34 /

+0.27 (+2.44%)

, PGEN

Precigen

$2.23 /

+0.025 (+1.13%)

, POSH

Poshmark

$15.38 /

+1.08 (+7.55%)

, CWH

Camping World

$32.49 /

-0.695 (-2.09%)

Welcome to this week’s…

ShowHide Related Items >><<
POSH Poshmark
$15.38 /

+1.08 (+7.55%)

PGEN Precigen
$2.23 /

+0.025 (+1.13%)

GTLB GitLab
$72.47 /

+11.02 (+17.93%)

FSR Fisker
$11.34 /

+0.27 (+2.44%)

CWH Camping World
$32.49 /

-0.695 (-2.09%)

ATUS Altice USA
$14.95 /

+0.01 (+0.07%)

ATUS Altice USA
$14.95 /

+0.01 (+0.07%)

01/24/22 Morgan Stanley
Altice USA price target lowered to $18 from $20 at Morgan Stanley
01/18/22 Exane BNP Paribas
Altice USA downgraded yesterday to Underperform at Exane BNP Paribas
01/03/22 Wolfe Research
Altice USA cut to Peer Perform at Wolfe Research as cable's competition rises
01/03/22 Wolfe Research
Altice USA downgraded to Peer Perform from Outperform at Wolfe Research
GTLB GitLab
$72.47 /

+11.02 (+17.93%)

02/04/22 RBC Capital
GitLab upgraded to Outperform from at RBC Capital on valuation
02/04/22 RBC Capital
GitLab upgraded to Outperform from Sector Perform at RBC Capital
01/27/22 JPMorgan
JPMorgan upgrades 'Growth All-Star' GitLab to Overweight
01/27/22 JPMorgan
GitLab upgraded to Overweight from Neutral at JPMorgan
FSR Fisker
$11.34 /

+0.27 (+2.44%)

11/10/21 BofA
Fisker price target raised to $24 from $18 at BofA
11/10/21 BofA
Tesla price target raised to $1,200 from $1,000 at BofA
11/09/21
Fly Intel: Top five analyst initiations
11/09/21 Credit Suisse
Fisker initiated with an Outperform at Credit Suisse
PGEN Precigen
$2.23 /

+0.025 (+1.13%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
02/25/21 Stifel
Precigen initiated with a Buy at Stifel
02/22/21 Wells Fargo
Precigen initiated with an Overweight at Wells Fargo
02/18/21
Fly Intel: Top five analyst initiations
POSH Poshmark
$15.38 /

+1.08 (+7.55%)

11/22/21 Guggenheim
Poshmark initiated with a Neutral at Guggenheim
11/16/21 Cowen
Poshmark downgraded to Market Perform from Outperform at Cowen
11/15/21 JMP Securities
Poshmark price target lowered to $30 from $54 at JMP Securities
11/10/21
Fly Intel: Top five analyst downgrades
CWH Camping World
$32.49 /

-0.695 (-2.09%)

11/04/21 Raymond James
Camping World price target raised to $54 from $47 at Raymond James
08/04/21
Fly Intel: Top five analyst upgrades
08/04/21 Baird
Camping World upgraded to Outperform on 'healthy' demand at Baird
08/04/21 Baird
Camping World upgraded to Outperform from Neutral at Baird
POSH Poshmark
$15.38 /

+1.08 (+7.55%)

PGEN Precigen
$2.23 /

+0.025 (+1.13%)

GTLB GitLab
$72.47 /

+11.02 (+17.93%)

FSR Fisker
$11.34 /

+0.27 (+2.44%)

CWH Camping World
$32.49 /

-0.695 (-2.09%)

ATUS Altice USA
$14.95 /

+0.01 (+0.07%)

  • 14
    Oct
  • 24
    Aug
FSR Fisker
$11.34 /

+0.27 (+2.44%)

POSH Poshmark
$15.38 /

+1.08 (+7.55%)

GTLB GitLab
$72.47 /

+11.02 (+17.93%)

FSR Fisker
$11.34 /

+0.27 (+2.44%)

CWH Camping World
$32.49 /

-0.695 (-2.09%)

ATUS Altice USA
$14.95 /

+0.01 (+0.07%)

POSH Poshmark
$15.38 /

+1.08 (+7.55%)

GTLB GitLab
$72.47 /

+11.02 (+17.93%)

FSR Fisker
$11.34 /

+0.27 (+2.44%)

CWH Camping World
$32.49 /

-0.695 (-2.09%)

ATUS Altice USA
$14.95 /

+0.01 (+0.07%)

Hot Stocks
Precigen announces 'positive' phase 1 data for PRGN-3006 in refractory AML » 17:08
12/13/21
12/13
17:08
12/13/21
17:08
PGEN

Precigen

$3.70 /

-0.15 (-3.90%)

Precigen "presented…

Precigen "presented positive interim data at the 63rd ASH Annual Meeting and Exposition from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T in patients with relapsed or refractory acute myeloid leukemia, or AML, and higher risk myelodysplastic syndromes. The oral presentation was delivered by David Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute and a lead investigator for the PRGN-3006 clinical trial. Today's ASH presentation included data from 15 r/r AML patients treated in the non-lymphodepletion cohort and the lymphodepletion cohort. Patients were heavily pre-treated with a median of 4 and 3 prior regimens in the non-lymphodepletion and the lymphodepletion cohorts, respectively. Additionally, 33% and 50% of the patients had failed prior allogeneic hematopoietic stem cell transplant in the non-lymphodepletion and the lymphodepletion cohorts, respectively. All patients received a single infusion of PRGN-3006."

ShowHide Related Items >><<
PGEN Precigen
$3.70 /

-0.15 (-3.90%)

PGEN Precigen
$3.70 /

-0.15 (-3.90%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
02/25/21 Stifel
Precigen initiated with a Buy at Stifel
02/22/21 Wells Fargo
Precigen initiated with an Overweight at Wells Fargo
02/18/21
Fly Intel: Top five analyst initiations
PGEN Precigen
$3.70 /

-0.15 (-3.90%)

  • 22
    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.